Polypeptides having antiviral activity and methods for use thereof
A polypeptide is provided that comprises an actinohivin variant polypeptide having an amino acid sequence selected from SEQ ID NOS: 4-12. The polypeptide can be provided as part of a fusion protein that includes the actinohivin variant polypeptide and either a fragment crystallizable domain of an antibody (Fc), a fragment antigen-binding domain of an antibody (Fab), or a single chain variable fragment of an antibody (scFv). Isolated nucleic acid molecules encoding the polypeptides are also provided along with vectors and plant cells capable of expressing the polypeptides. Methods of treating an infection of a subject by an enveloped virus are further provided and include administering an effective amount of the polypeptides to a subject.
1. A method of treating an infection of a subject by an enveloped virus, comprising administering to the subject an effective amount of an actinohivin variant polypeptide having an amino acid sequence selected from SEQ ID NOS: 4-12.
2. The method of claim 1 , wherein the enveloped virus is selected from a human immunodeficiency virus (HIV), an influenza virus, a hanta virus, a hepatitis C virus, a herpes virus, a severe acute respiratory syndrome coronavirus (SARS-CoV), a metapneumovirus, a henipavirus, a flavivirus, and a hemorrhagic fever virus.
3. The method of claim 2 , wherein the enveloped virus is HIV.
4. The method of claim 1 , wherein administering the actinohivin variant polypeptide comprises topically administering the actinohivin variant polypeptide.
5. The method of claim 1 , wherein the actinohivin variant polypeptide comprises the amino acid sequence of SEQ ID NO: 4.
6. The method of claim 1 , further comprising administering a second polypeptide selected from: a fragment crystallizable domain of an antibody (Fc); a fragment antigen-binding domain of an antibody (Fab); and a single chain variable fragment of an antibody (scFv), wherein the actinohivin variant polypeptide and the second polypeptide comprise a fusion protein.
7. The method of claim 6 , wherein the antibody is a monoclonal antibody.
8. The method of claim 6 , wherein the second polypeptide is Fab.
9. The method of claim 6 , wherein the second polypeptide is scFv.
10. The method of claim 6 , wherein the second polypeptide is Fc.
11. The method of claim 6 , wherein the polypeptide further comprises a peptide linker for connecting the actinohivin variant polypeptide to the second polypeptide.
12. The method of claim 11 , wherein the peptide linker comprises an amino acid sequence of SEQ ID NO: 13.
13. A method of treating an infection of a subject by an enveloped virus, comprising administering to the subject an effective amount of:
a first polypeptide comprising an actinohivin variant polypeptide having an amino acid sequence selected from SEQ ID NOS: 4-12; and
a second polypeptide selected from the group consisting of a fragment crystallizable domain of an antibody (Fc), a fragment antigen-binding domain of an antibody (Fab), and a single chain variable fragment of an antibody (scFv),
wherein the first polypeptide and the second polypeptide comprise a fusion protein.
14. The method of claim 13 , wherein the polypeptide further comprises a peptide linker for connecting the actinohivin variant polypeptide to the second polypeptide.
15. The method of claim 14 , wherein the peptide linker comprises an amino acid sequence of SEQ ID NO: 13.